Arkema (AKE) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Q1 2026 volumes remained stable year-over-year, with growth in all Specialty Materials segments and a notable improvement in March after a slow start to the year, especially in Asia.
Specialty Materials volumes rose 1.5%, driven by batteries, sport, 3D printing, and healthcare, with batteries showing robust growth of ~15% year-over-year.
EBITDA reached €283 million, up 14% sequentially from Q4 2025 but down 14% year-on-year, with a margin of 13.0%, impacted by a €20 million negative currency effect and weak U.S./Europe demand.
The company managed cost inflation and supply chain disruptions from the Middle East conflict, initiating strong pricing actions since March to offset higher input costs.
Major growth projects progressed, including new PVDF capacity in the U.S. (mid-2026 start), a 20% expansion in China (2028), and the successful ramp-up of the Singapore PA 11/Rilsan Clear plant.
Financial highlights
Q1 2026 revenue was €2,182 million, down 8.4% year-on-year, impacted by a 5.1% negative currency effect and a 3% negative price effect.
Q1 EBITDA was €283 million; recurring EBIT was €118 million (5.4% margin); adjusted net income was €65 million (€0.86/share).
Non-recurring items totaled €45 million, including €34 million PPA depreciation and €11 million restructuring costs.
Q1 recurring cash flow was -€95 million, reflecting typical seasonal working capital needs and improved year-over-year.
Net debt (including hybrids) at March 2026 was €3,344 million; net debt/EBITDA ratio at 2.8x.
Outlook and guidance
Q2 2026 expected to show sequential improvement, with EBITDA targeted to be comparable to Q2 2025, supporting full-year guidance of slight EBITDA growth at constant exchange rates.
Major projects are expected to deliver around €50 million additional EBITDA in 2026 versus 2025.
Price increases to offset input cost inflation will become visible in Q2.
The company remains agile in pricing and operational controls amid ongoing Middle East conflict and global uncertainties.
Capex is managed at ~€600 million for 2026.
Latest events from Arkema
- EBITDA dropped but cash flow and cost savings were strong, with Asia and growth markets outperforming.AKE
Q4 202526 Feb 2026 - Q2 2024 EBITDA rose 8.2% on 3.8% sales growth, with guidance raised for the year.AKE
Q2 20242 Feb 2026 - Q3 2024 EBITDA rose 5.4% to €407 million, margin at 17.0%, amid weak demand and tight debt control.AKE
Q3 202416 Jan 2026 - Ambitious growth, innovation, and sustainability drive strong specialty materials performance.AKE
BNPP Exane CEO Conference Presentation13 Jan 2026 - Q3 2024 saw higher sales and EBITDA, with strong specialty materials growth and sustainability focus.AKE
BOFA European Materials Conference 2024 Presentation13 Jan 2026 - Solid Q2 growth and sustainability focus drive higher 2024 EBITDA outlook of €1.53–1.63bn.AKE
Investor presentation13 Jan 2026 - Strong specialty materials growth, resilient margins, and major investments drive future expansion.AKE
Morgan Stanley Chemicals Cannonball Run Field Trip Presentation13 Jan 2026 - EBITDA margin held at 15.2% in Q2 2025, with cost-saving targets doubled for the year.AKE
Q2 202513 Jan 2026 - 2024 EBITDA rose 2.1% to €1.53bn, led by Specialty Materials and Asian growth.AKE
Q4 202418 Dec 2025